

Freedom of Information Act 2000 - Request Reference Fol/20/475
Antiretroviral Therapies

Request details

I am analysing the usage of antiretroviral therapies. Could you please answer the following four questions?

Q1. How many patients were treated (for any condition) in the latest 6-month period with the following drugs:

- Juluca (rilpivirine/dolutegravir) 2
- Dovato (lamivudine/dolutegravir) 65
- Triumeq (abacavir/lamivudine/dolutegravir) 178
- Tivicay (dolutegravir) 114
- Isentress (raltegravir) 49
- Biktarvy (TAF/emtricitabine/bictegravir) 150
- Genvoya (TAF/emtricitabine/elvitegravir/cobisistat) 49
- Symtuza (TAF/emtricitabine/darunavir/cobisistat) 94
- Odefsey (TAF/emtricitabine/rilpivirine) 47
- Descovy (TAF/emtricitabine) 146
- Truvada or generic TDF/emtricitabine 228

Q2. How many patients received any antiretroviral (ART) therapy for HIV treatment (excluding pre-exposure prophylaxis):

- for the latest 6-month period
- for the 6 months from July-December 2019

In 2020 – 47 patients received ART

In 2019 – 85 patients received ART

Q3. How many patients were treated in the latest 6-months period with Truvada or generic TDF/emtricitabine for:

- HIV treatment
- Pre-exposure prophylaxis (PrEP)

188 patients were treated with Truvada

Q4. How many packs of Truvada or generic TDF/emtricitabine were dispensed in latest 6-month period for:

- HIV treatment
- Pre-exposure prophylaxis (PrEP)

496 packs of Truvada were dispensed